FASN inhibitor G28UCM inhibited the growth of HER2+ BC and even in patients with acquired resistance to anti-HER2 drugs, which may provide a new way to treat trastuzumab-resistant BC [125]. The gene discussed is FASN; the disease is breast cancer.